Brought to you by 
Mylan Laboratories acquires Penederm in all-stock transaction
13 Jul 1999
Executive Summary
Mylan Laboratories has acquired Penederm for stock. Penederm shareholders get 0.68 share of Mylan for each share held. The agreement is valued at about $205mm based on Mylan's recent closing price on June 23, 1998.
Deal Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mylan Laboratories acquires Penederm in all-stock transaction
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice